Australian specialist pharmaceutical company Hatchtech has appointed former Phosphagenics Vice President Hugh Alsop as Chief Executive Officer.
Dr Ross Macdonald, who has resigned as CEO, will return to the Board to resume his Non-Executive Director role.
Macdonald’s leadership took the company through a transitional period in which it concluded a successful Phase IIb study and end of Phase II consultation with the US FDA for its lead product DeOvo, a single application topical treatment for head lice, and completed a A$6m financing to position the company to begin its Phase III programme this year.
Dr Macdonald has decided to resign to pursue other interests, while remaining on the Hatchtech board.
Alsop’s roles prior to Phosphagenics include Director of Business Development at Acrux from 2006–2012. He has also worked for Sigma Pharmaceuticals and Mayne Pharma (formerly Faulding Pharmaceuticals) in a variety of roles.
He said: ‘The next 12 months will require a dedicated and focused execution of the company’s clinical, regulatory and commercial plans, and I look forward to leading this programme to ensure the value of DeOvo is maximised for Hatchtech shareholders.’
